ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Spinocerebellar ataxia, autosomal recessive type 23 (SCAR23) with compound TDP2 variants: clinical, molecular, and quantitative follow-up.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinocerebellar ataxia, autosomal recessive type 23 (SCAR23) is an ultra-rare inherited disorder caused by biallelic Loss-of-Function (LoF) variants in TDP2, a nuclear enzyme involved in DNA double-strand breaks repair. To date, only 12 cases with homozygous variants and complex neurological phenotypes have been reported. CASE DESCRIPTION: We describe a 20-year-old male presenting with cerebellar ataxia, drug-resistant epilepsy, mild intellectual disability, and recurring craniofacial traits observed in SCAR23. Additional findings included polycythemia and a pituitary hamartoma. Clinical exome sequencing (CES) identified two novel TDP2 nonsense variants. In silico and structural analyses indicated that both variants affect highly conserved residues in the catalytic domain. Longitudinal video-oculography confirmed downbeat nystagmus (DBN), while static stabilometry captured subtle postural changes over 12 months not detected by routine clinical examination, highlighting the utility of quantitative digital assessments. DISCUSSION: This case expands the genotypic spectrum of SCAR23 and highlights recurring facial traits that may aid recognition. The coexisting SHOX deletion (i.e., Leri-Weill syndrome) was considered unrelated to the neurological phenotype. Digital assessments provided objective measures of motor function over time.
conclusionsOur findings broaden the clinical and molecular characterization of SCAR23 and illustrate the potential of digital biomarkers for longitudinal monitoring. Despite the lack of functional validation and the inherent limitations of a single-case report, these observations provide valuable insights for future research in this ultra-rare disorder.
Indexed as
Identifiers
41457191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.